Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502917 | 0.83 | TAAR1 (0.45) | TAAR1ADRA1ASOS1HTR2ASLC6A4 | |
| SCHEMBL5496489 | 0.83 | SLC6A4 (0.49) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5502055 | 0.77 | TAAR1 (0.44) | TAAR1ADRA1ASOS1HTR2ASLC6A4 | |
| SCHEMBL5497104 | 0.76 | SOS1 (0.38) | TAAR1ADRA1ASOS1HTR2ASLC6A4 | |
| SCHEMBL5502216 | 0.76 | SLC6A4 (0.42) | TAAR1ADRA1AHTR2ASLC6A4KCNH2 | |
| SCHEMBL5497523 | 0.74 | HTR2A (0.43) | TAAR1ADRA1AHTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL6000435 | 0.73 | SOS1 (0.38) | TAAR1ADRA1ASOS1HTR2ASLC6A4 | |
| SCHEMBL5497370 | 0.72 | SOS1 (0.41) | TAAR1SOS1 | |
| SCHEMBL6000440 | 0.72 | HTR1D (0.39) | TAAR1ADRA1ACYP1A2 | |
| SCHEMBL24163263 | 0.71 | TAAR1 (0.63) | TAAR1ADRA1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | claimed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | TAAR1 283/4885ADRA1A 512/4885SOS1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.